Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Interface between BCR-ABL-Dependent and -Independent Resistance Signaling Pathways in Chronic Myeloid Leukemia

24 Apr 2012

Abstract excerpt

Chronic myeloid leukemia (CML) is a clonal hematopoietic disorder characterized by the presence of the Philadelphia chromosome which resulted from the reciprocal translocation between chromosomes 9 and 22. The pathogenesis of CML involves the constitutive activation of the BCR-ABL tyrosine kinase, which governs malignant disease by activating multiple signal transduction pathways. The BCR-ABL kinase inhibitor,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Chronic Myeloid Leukemia Treatments
Share to Eosinophilic Disorders and Syndromes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23259070
DOI: 10.1155/2012/671702

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Interface between BCR-ABL-Dependent and -Independent Resistance Signaling Pathways in Chronic Myeloid LeukemiaPMID 23259070Read ↗

Therapeutic Targets for Overcoming BCR::ABL1 Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia.Semantic proximity Read ↗

Resistance in chronic myeloid leukemia: definitions and novel therapeutic agentsSemantic proximity Read ↗

New Insights into the Pathophysiology of Chronic Myeloid Leukemia and Imatinib ResistanceSemantic proximity Read ↗

Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An UpdateSemantic proximity Read ↗

BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid LeukemiaSemantic proximity Read ↗

Therapeutic Targeting of BCR-ABL: Prognostic Markers of Response and Resistance Mechanism in Chronic Myeloid LeukaemiaSemantic proximity Read ↗

Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors.Semantic proximity Read ↗

Chronic myeloid leukemia: advances in understanding disease biology and mechanisms of resistance to tyrosine kinase inhibitors.Semantic proximity Read ↗

Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapySemantic proximity Read ↗

Contribution of BCR-ABL molecular variants and leukemic stem cells in response and resistance to tyrosine kinase inhibitors: a reviewSemantic proximity Read ↗

Mechanisms underlying therapeutic resistance of tyrosine kinase inhibitors in chronic myeloid leukemiaSemantic proximity Read ↗

Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.